Qian Shi

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

• Small Cell and Large Cell Neuroendocrine Carcinoma of the Colon and Rectum: Population-Based Analysis of Incidence, Survival, and Site-Specific Outcomes

  Cancers · 2026-06-18

• Figure S10 from Leveraging AI to Evaluate Minimal Residual Disease Endpoint Surrogacy in Multiple Myeloma

  2026-06-17

• Figure S4 from Leveraging AI to Evaluate Minimal Residual Disease Endpoint Surrogacy in Multiple Myeloma

  2026-06-17

• Table 2 from Leveraging AI to Evaluate Minimal Residual Disease Endpoint Surrogacy in Multiple Myeloma

  2026-06-17

• Table 1 from Leveraging AI to Evaluate Minimal Residual Disease Endpoint Surrogacy in Multiple Myeloma

  2026-06-17

• Figure S7 from Leveraging AI to Evaluate Minimal Residual Disease Endpoint Surrogacy in Multiple Myeloma

  2026-06-17

• Figure S3 from Leveraging AI to Evaluate Minimal Residual Disease Endpoint Surrogacy in Multiple Myeloma

  2026-06-17

• Descriptive notes for supplement from Leveraging AI to Evaluate Minimal Residual Disease Endpoint Surrogacy in Multiple Myeloma

  2026-06-17

• Table 3 from Leveraging AI to Evaluate Minimal Residual Disease Endpoint Surrogacy in Multiple Myeloma

  2026-06-17

• Figure S5 from Leveraging AI to Evaluate Minimal Residual Disease Endpoint Surrogacy in Multiple Myeloma

  2026-06-17

• Data from Leveraging AI to Evaluate Minimal Residual Disease Endpoint Surrogacy in Multiple Myeloma

  2026-06-17

• Figure 1 from Leveraging AI to Evaluate Minimal Residual Disease Endpoint Surrogacy in Multiple Myeloma

  2026-06-17

• Figure S1 from Leveraging AI to Evaluate Minimal Residual Disease Endpoint Surrogacy in Multiple Myeloma

  2026-06-17

• Figure S2 from Leveraging AI to Evaluate Minimal Residual Disease Endpoint Surrogacy in Multiple Myeloma

  2026-06-17

• Table 4 from Leveraging AI to Evaluate Minimal Residual Disease Endpoint Surrogacy in Multiple Myeloma

  2026-06-17

• Figure S8 from Leveraging AI to Evaluate Minimal Residual Disease Endpoint Surrogacy in Multiple Myeloma

  2026-06-17

• Figure S9 from Leveraging AI to Evaluate Minimal Residual Disease Endpoint Surrogacy in Multiple Myeloma

  2026-06-17

• Figure S12 from Leveraging AI to Evaluate Minimal Residual Disease Endpoint Surrogacy in Multiple Myeloma

  2026-06-17

• Figure S6 from Leveraging AI to Evaluate Minimal Residual Disease Endpoint Surrogacy in Multiple Myeloma

  2026-06-17

• Figure S11 from Leveraging AI to Evaluate Minimal Residual Disease Endpoint Surrogacy in Multiple Myeloma

  2026-06-17